Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
22 oct. 2024 07h00 HE
|
Teva Pharmaceutical Industries Ltd
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved...
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
03 oct. 2024 08h30 HE
|
Teva Pharmaceutical Industries Ltd; mAbxience
The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024The collaboration supports Teva's Pivot to Growth strategy and adds...
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
17 mai 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Welcomes Biopharma Executive Dr. Ram Petter to Drive Strategic Collaborations
Connectyx Technologies Holdings Group Returns to OTC Current Status
13 avr. 2020 09h30 HE
|
Connectyx Technologies Holdings Group, Inc
More than $350,000 of Convertible Debt Eliminated BOCA RATON, FL, April 13, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group (OTC PINK: CTYX) has filed all required annual reports...
Console Mattiacci Law on Behalf of 13 Former Employees Bring Suit Against Teva for Not Paying Separation Pay Owed
24 juin 2019 14h47 HE
|
Console Mattiacci Law, LLC
PHILADELPHIA, June 24, 2019 (GLOBE NEWSWIRE) -- A lawsuit was filed on June 20, 2019 in Montgomery County, Pennsylvania against Teva Pharmaceuticals USA, Inc. and Teva Branded Pharmaceuticals...
Console Mattiacci Law Obtains 6.314 Million Dollar Verdict in Discrimination and Retaliation Case Against Teva Pharmaceuticals USA, Inc.
20 nov. 2018 09h45 HE
|
Console Mattiacci Law, LLC
PHILADELPHIA, Nov. 20, 2018 (GLOBE NEWSWIRE) -- A unanimous jury in Philadelphia federal court found in favor of Stephen Middlebrooks and concluded that he was retaliated against and subject to a...
Cocrystal Pharma Provides Update on Reverse Stock Split
23 janv. 2018 16h30 HE
|
Cocrystal Pharma, Inc.
- Reverse stock split to be effective on Wednesday, January 24, 2018 on split-adjusted basis under trading symbol “COCPD” - ATLANTA, GA and BOTHELL, WA, Jan. 23, 2018 (GLOBE NEWSWIRE) --...
Cocrystal Pharma Announces 1-for-30 Reverse Stock Split
23 janv. 2018 09h15 HE
|
Cocrystal Pharma, Inc.
– Reverse stock split positions Company to uplist to the NASDAQ Capital Market in Q1 2018 – – Company expects to commence Phase 2a study in Q1 2018 for lead program, CC-31244, for the treatment of...
Cocrystal Pharma Announces Filing 2017 Third Quarter Financial Statements and Provides Company Update
08 nov. 2017 17h30 HE
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced...
Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Teva Pharmaceutical Industries Limited (NYSE: TEVA) Securities Case
08 déc. 2016 11h06 HE
|
Scott + Scott, Attorneys at Law, LLP
NEW YORK, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 5, 2017 is the last day to...